China Clears IASO208 for Clinical Study

IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.

IASO Bio disclosed November 11 that China cleared the IND for IASO208, a CD20-targeted in-vivo CAR-T program. IND clearance allows a trial; it is not an efficacy determination or marketing approval.